Purpose Patients receiving high-dose I-131 to treat differentiated thyroid cancer are isolated
from visitors to limit radiation exposure to reasonable levels. The appropriate isolation time …

PURPOSE: Effective half life of I-131 (T (eff)) in patients with differentiated thyroid cancer
treated by I-131 is must-know value for dose calculation and determination of release time …

Postoperative 131 I treatment for differentiated thyroid cancer (DTC) can create a radiation
hazard for nearby persons. The present prospective study aimed to investigate radiation …

In patients with differentiated thyroid carcinoma (DTC) who after thyroidectomy underwent
radioiodine-131 ((131) I) treatment for the ablation of the thyroid remnant, isolation period is …

Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid
cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment …

Purpose To formulate radiation precautions for patients with thyroid cancer who are
undergoing thyroid hormone withdrawal–induced hypothyroidism and iodine 131 (131I) …

Radioiodine therapy has been widely used for ablation of remnant tissue after surgical
treatment of differentiated thyroid carcinoma (DTC). Internal dosimetry provides a new …

A previously published model (Atkins) allows for calculation of 131 I maximum tolerated
activity on the basis of 48-hour whole-body retention of 131 I on a pretherapy diagnostic …

Purpose The residence time of 131 I in the blood is likely to be a measure of the amount of
131 I that is available for uptake by thyroid remnant tissue and thus the radiation absorbed …

Background: Patients with differentiated thyroid cancers (DTC) who receive radioactive
iodine-131 (RAI) are released from isolation when their dose rate is below the regulatory …